Dimensional Fund Advisors’s Enliven Therapeutics ELVN Stock Holding History

Dimensional Fund Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$34.1M	Buy	743,898 +72,486	+11%	+$3.95M	0.01%	1782
2026 Q2	$34.1M	Sell	671,412 -10,303	-2%	-$437K	0.01%	1800
2026 Q1	$26.7M	Buy	681,715 +282,822	+71%	+$7.84M	0.01%	1837
2025 Q4	$6.14M	Buy	398,893 +238,434	+149%	+$4.75M	﹤0.01%	2462
2025 Q3	$3.28M	Buy	160,459 +113,608	+242%	+$2.29M	﹤0.01%	2646
2025 Q2	$942K	Buy	+46,851	New	+$887K	﹤0.01%	2901
2023 Q3	–	Sell	-23,762	Closed	-$485K	–	3482
2023 Q2	$485K	Buy	23,762 +13,847	+140%	+$280K	﹤0.01%	3071
2023 Q1	$217K	Buy	+9,915	New	+$202K	﹤0.01%	3187
2022 Q3	$64K	Buy	+7,066	New	+$41.7K	﹤0.01%	3377

Other funds holding ELVN

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Dimensional Fund Advisors's ELVN Position: Q3 2026 in Review

Dimensional Fund Advisors increased its Enliven Therapeutics (ELVN) stake by 11% in Q3 2026, buying an estimated $3.95M and bringing the position to 743,898 shares worth $34.1M. The position accounts for 0.01% of the portfolio, ranked #1782.

Dimensional Fund Advisors first reported a position in ELVN in Q3 2022 and has held it in 9 quarters since. 38 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

Dimensional Fund Advisors held 743,898 shares of Enliven Therapeutics worth $34.1M as of Q3 2026.
Dimensional Fund Advisors bought 72,486 Enliven Therapeutics shares in Q3 2026, an estimated $3.95M.
Enliven Therapeutics made up 0.01% of Dimensional Fund Advisors's portfolio in Q3 2026, its #1782 holding.
Dimensional Fund Advisors first reported a position in Enliven Therapeutics in Q3 2022 and has held it in 9 quarters since.
38 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.